Clinical Trials
10 trialsNCT01625351 2026-02-06
A Study of CD45RA+ Depleted Haploidentical Stem Cell Transplantation in Children With Relapsed or Refractory Solid Tumors and Lymphomas
St. Jude Children's Research Hospital
Phase 1 Completed
NCT03989466 2024-10-10
Itacitinib and Alemtuzumab in Treating Patients With T-Cell Prolymphocytic Leukemia
M.D. Anderson Cancer Center
Phase 1 Completed
NCT02689453 2022-04-29
Subcutaneous Recombinant Human IL-15 (s.c. rhIL-15) and Alemtuzumab for People With Refractory or Relapsed Chronic and Acute Adult T-cell Leukemia (ATL)
National Institutes of Health Clinical Center (CC)
Phase 1 Completed
NCT00057005 2020-01-18
ADVL
Baylor College of Medicine
Phase 1 Completed
NCT00323323 2017-01-20
CHOP and Campath-1H in Previously Untreated Aggressive T/NK-Cell Lymphomas
Ohio State University Comprehensive Cancer Center
Phase 1 Completed
NCT00104975 2016-12-15
Alemtuzumab and Combination Chemotherapy Followed By Donor Lymphocytes in Treating Patients Who Are Undergoing Donor Stem Cell Transplant for Hematologic Cancer
Yale University
Phase 1 Completed
NCT00330252 2016-05-13
Weekly Subcutaneous Alemtuzumab and Rituximab for Relapsed CLL
Dana-Farber Cancer Institute
Phase 1 Completed
NCT00923182 2015-04-30
A Safety Confirmatory Study of Alemtuzumab in Japanese Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia
Sanofi
Phase 1 Completed
NCT00458250 2008-11-18
Feasibility of Haploidentical Hematopoietic Stem Cell Transplantation Using CAMPATH-1H
Tehran University of Medical Sciences
Phase 1 Completed
NCT00161590 2008-10-22
Study of CHOP + Campath for T-Cell, Null Cell, or Natural Killer (NK)-Cell Lymphoma
Weill Medical College of Cornell University
Phase 1 Completed